Home
    • Plans Blog Contact
    NOVARTIS AG logo

    NOVARTIS AG

    NVSEF
    Last price US$151.90
    Market cap US$289.8b
    12M price change 26.06%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    BRISTOL MYERS SQUIBB COBMYMP Industry peer SanofiSNYNF Industry peer ASTRAZENECA PLCAZNCF Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    NOVARTIS AG Overview

    Industry: Drug Manufacturers-General

    Sector: Healthcare

    Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for NOVARTIS AG into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Apr 28, 2026

    Quarterly result summary

    EPS was $1 (reported).

    EPS $1 reported

    What changed

    • EPS reported to $1.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 6-K Jun 11, 2026 Earnings release 99.2 CONDENSED FINANCIAL REPORT Apr 28, 2026 Earnings release 99.1 FINANCIAL REPORT Q4 2025 Feb 04, 2026 Earnings release 99.2 CONDENSED FINANCIAL REPORT Feb 04, 2026 SEC filing 20-F Feb 04, 2026 SEC filing FORM 6-K Nov 25, 2025 SEC filing FORM 6-K Nov 20, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 2.00/5
    NOVARTIS AG earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers-General industry , BRISTOL MYERS SQUIBB CO , Sanofi , ASTRAZENECA PLC are companies with high ratings.

    Return on Equity

    Score 1.96/5
    NOVARTIS AG exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    NOVARTIS AG NVSEF US$289.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    NOVARTIS AG olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    NOVARTIS AG NVSEF US$289.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Drug Manufacturers-General industry , BRISTOL MYERS SQUIBB CO , Sanofi , ASTRAZENECA PLC are companies with high ratings.

    Leverage

    Score 1.83/5
    NOVARTIS AG registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    NOVARTIS AG NVSEF US$289.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    NOVARTIS AG logo

    NOVARTIS AG

    US$151.90

    US$289.8b

    -5.06%

    26.06%